Cerevel Therapeutics, LLC

Quick facts

Phase 1 pipeline

• [11C]-LY2795050
• [14C]-darigabat
• CVL-231
• CVL-354
• CVL-751
• CVL-865 High dose
• CVL-865 low dose
• Tavapadon [14C] suspension
• Tavapadon tablet

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cerevel Therapeutics, LLC portfolio CI brief
• Cerevel Therapeutics, LLC pipeline updates RSS

Related

• Sector hub: All tracked pharma companies